An observational study in Breast Cancer, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Breast Neoplasms by Sohag University — 12 open to participants now, 13 under way, none of them phase 3. Breast Neoplasms · Sohag University.
Among the 19 studies in Breast Neoplasms by Sohag University, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 17th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →12 of the 19 studies in Breast Neoplasms by Sohag University are open now, in 1 country. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18+ · Women only
Sohag University · Sites in Egypt
Women only
Sohag University · Sites in Egypt
Women only
Sohag University
Ages 18–90 · Women only
Sohag University · Sites in Egypt
Ages 26–85 · Women only
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 100 is below the median of 184 across 3,237 observational studies indexed under Breast Neoplasms.
Median enrollment 60 across the 5 interventional studies, 100 across the 14 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
3 of the studies in Breast Neoplasms by Sohag University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872332Sohag UniversityFDG PET/CT Radiomics for True Oligometastatic Breast Cancer | 2027-06-01 |
| NCT07750340Sohag UniversityBreast Cancer Molecular Subtypes and Skeletal Metastases Patterns on Bone Scintigraphy | 2027-07 |
| NCT07758127Sohag UniversityUpdates and Insights on HER2 in Breast Cancer in Sohag Governorate | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Breast Neoplasms by Sohag University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy.
The study will include adult male and female patients aged 18 to 80 years with histopathologically confirmed breast cancer who are referred for whole-body bone scintigraphy.
The main questions it aims to answer are:
The study will include 100 patients diagnosed with histologically proven breast cancer who are referred to the Nuclear Medicine Department for Technetium-99m labeled diphosphonates (Tc99m-MDP )whole-body bone scintigraphy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Presence of skeletal metastases on Tc-99m MDP whole-body bone scintigraphy.
Number of participants with skeletal metastases detected by Tc-99m MDP whole-body bone scintigraphy according to breast cancer molecular subtype.
Time frame: Baseline
Anatomical distribution of skeletal metastases.
Anatomical distribution of skeletal metastases (axial skeleton, appendicular skeleton or mixed) according to breast cancer molecular subtype.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.